Saudi Arabia Human Milk Oligosaccharides Market Size & Outlook, 2026-2034

Saudi Arabia Human Milk Oligosaccharides Market Insights

As highlighted in Deep Market Insights analysis, the Saudi Arabia Human Milk Oligosaccharides Market, worth USD 6.65 Million in 2025, is forecasted to achieve USD 27.7 Million by 2034.
The Saudi Arabia market is anticipated to grow at a CAGR of 17.1% during the period 2026–2034.
By 2025, 2-Fucosyllactose (2-FL) represented the largest share of the Product Type market size.
2-Fucosyllactose (2-FL) is expected to remain the key growth driver within Product Type, registering the fastest CAGR during the forecast period.

In 2025, Saudi Arabia represented 1.91% of the overall global Human Milk Oligosaccharides Market size.
United States is projected to lead the global Human Milk Oligosaccharides Market size by 2034.
Across Middle East and Africa, United Arab Emirates is anticipated to hold the dominant position in market size by 2034.
Egypt is forecasted to expand at the fastest pace in Middle East and Africa, attaining USD 16.95 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 6.65 Million
Market Size In 2034	USD 27.7 Million
Largest segment	2-Fucosyllactose (2-FL)
Units	Revenue in USD Million
CAGR	17.1% (2026-2034)
Segmnetation Covered
Product Type	2-Fucosyllactose (2-FL) 3-Fucosyllactose (3-FL) Lacto-N-neotetraose (LNnT) Others
Application	Infant formula Dietary supplements Functional foods and beverages Animal nutrition
Form	Dry Liquid
End user	Infant nutrition manufacturers Nutraceutical manufacturers Food and beverage companies
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Product Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
2-Fucosyllactose (2-FL)	XX.x	XX.x	XX.x	2.96	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
3-Fucosyllactose (3-FL)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lacto-N-neotetraose (LNnT)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Infant formula	XX.x	XX.x	XX.x	2.71	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Dietary supplements	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Functional foods and beverages	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Animal nutrition	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

Source: DMI Analysis Company Publications, Primary Interviews.

End user	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Infant nutrition manufacturers	XX.x	XX.x	XX.x	3.46	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Nutraceutical manufacturers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Food and beverage companies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x